{"SPADE_UN_18728": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_18728", "Peptide Name": "Brevicillin (natural AMPs; lantipeptide, bacteriocin, Gram-positive bacteria, prokaryotes; UCSS1b)", "Source": "Brevibacillus sp. strain AF8", "Family": "Not found", "Gene": "Not found", "Sequence": "SDSVVSDIICTTFCSVTWCQSNCC", "Sequence Length": 24, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Antiviral", "Antifungal", "Antifungal", "Hemolytic"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2601.93, "PI": 4.05, "Hydrophobicity": 0.66, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Singh SS, Sharma D, Singh C, Kumar S, Singh P, Sharma A, Das DK, Pinnaka AK, Thakur KG, Ringe RP, Korpole S.2023", "Reference": "J Appl Microbiol. 2023 Mar 13:lxad054. doi: 10.1093/jambio/lxad054.PubMed", "Title": "Brevicillin, a novel lanthipeptide from the genus Brevibacillus with antimicrobial, antifungal and antiviral activity."}], "Frequent Amino Acids": "CST", "Absent Amino Acids": "AEGHKLMOPRUY", "Basic Residues": 0, "Acidic Residues": 2, "Hydrophobic Residues": 7, "Polar Residues": 18, "Positive Residues": 0, "Negative Residues": 2, "Net Charge": -2, "Comments": "Discovery: genome mining and sequence alignment. Antimicrobial substance was extracted from cell free fermented broth using diaion HP20 resin and subsequently purified by HPLC.Sequence analysis: APD analysis reveals this sequence is most similar (41.38%) toThuricin 4A-4C=S: 21%; V=T: 13%. GRAVY: 0.66; M Wt: 2601.967; Mol formula:  C106H167N26O39S5; molar extinction coeff: 5550.Chemical modification: not yet fully established.Activity: killed S. aureus MTCC 1430 (MIC 0.8 ug/ml), E. coli MTCC 1610 (MIC 1.2 ug/ml), and C. albicans MTCC 183 (MIC 30-45 ug/ml) in 30 min at 4 ug/ml, 6 ug/ml and 20 ug/ml, respectively. It inhibited ~99% viral growth of SARS-Cov-2 at 10 ug/ml.Antimicrobial robustness: activity is retained between pH 4-10. Heat-stable at 100oC. But autoclave can disrupt the activity!MOA: damaged cell envelope (SEM). ATP release was detected.Toxicity: highly hemolytic (HC50 6 ug/ml). HEK 293T (LC50 25-50 ug/ml) and vero cells (LC50 25 ug/ml).", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_18728", "Similarity": 1.0, "Sequence": "SDSVVSDIICTTFCSVTWCQSNCC"}, {"SPADE_ID": "SPADE_UN_14712", "Similarity": 0.5555555555555556, "Sequence": "DWLRIIWDWVCSVVSDFK"}]}}}